

Please fax a copy (front and back) of all the patient's pharmacy and medical insurance cards as well as any relevant clinical notes/documents

Patient Demographics		Provider Information	
Name _____ Sex <input type="checkbox"/> M <input type="checkbox"/> F		Prescriber _____	
DOB _____ SSN _____		NPI _____ DEA _____	
Phone _____ 2 nd Phone _____		Practice Name _____	
Address _____ Apt/Suite _____		Address _____	
City, State, ZIP _____		City, State, ZIP _____	
Primary language, if other than English _____		Phone _____ Fax _____ Key contact _____	
This is a <input type="checkbox"/> New Rx <input type="checkbox"/> Refill	Training by <input type="checkbox"/> Prescriber's office <input type="checkbox"/> Pharmacy to facilitate <input type="checkbox"/> Not needed	Ship first fill to <input type="checkbox"/> Prescriber's office <input type="checkbox"/> Patient <input type="checkbox"/> Other _____	

Clinical Information			
Diagnosis	Date of diagnosis _____	BSA affected(%) _____	Date of negative TB test _____
<input type="checkbox"/> L20.9 Atopic dermatitis, unspecified		List areas affected _____	or Check here if <input type="checkbox"/> TB test pending, will fax results
<input type="checkbox"/> L40.0 Psoriasis vulgaris			HBV negative or treated <input type="checkbox"/> Yes <input type="checkbox"/> No
<input type="checkbox"/> L40.5 Psoriatic arthritis		Prior treatments & reason for discontinuation _____	Weight _____ <input type="checkbox"/> lb <input type="checkbox"/> kg Height _____ <input type="checkbox"/> in
<input type="checkbox"/> L40.8 Other psoriasis			Allergies _____
<input type="checkbox"/> L40.9 Psoriasis, unspecified			Other notes _____
<input type="checkbox"/> L73.2 Hidradenitis suppurativa			
<input type="checkbox"/> Other (include ICD-10) _____			

AAD Consensus Statement on Psoriasis Therapies
 Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationship.
 Psoriasis is covering greater than 10% of BSA. Psoriasis is on palms, soles, head and neck, or genitalia. Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints.

Medication	Directions	Quantity	Refills
<input type="checkbox"/> Cimzia [®] 200mg (certolizumab pegol)	<input type="checkbox"/> Inject 400mg (2 syringes) SQ every other week. <u>Alternative dosing for patients ≤ 90kg:</u> <input type="checkbox"/> Initial: Inject 400mg (2 syringes) SQ initially and at weeks 2 and 4. <input type="checkbox"/> Maintenance: Beginning week 6, inject 200mg SQ every OTHER week.	4 syringes 6 syringes 2 syringes	_____ Zero _____ Zero
<input type="checkbox"/> Cosentyx [®] 150mg (secukinumab)	Initial: <input type="checkbox"/> Inject 300mg SQ at weeks 0, 1, 2, and 3. <input type="checkbox"/> Inject 150mg SQ at weeks 0, 1, 2, and 3. Maintenance: <input type="checkbox"/> Beginning week 4, inject 300mg SQ once every 4 weeks. <input type="checkbox"/> Beginning week 4, inject 150mg SQ once every 4 weeks. <input type="checkbox"/> Other _____	8 pens/syringes 4 pens/syringes 2 pens/syringes 1 pen/syringe <input type="checkbox"/> Other _____	Zero Zero _____ _____
<input type="checkbox"/> Dupilumab [®] 300mg (dupilumab)	<input type="checkbox"/> Initial: Inject 600mg (2 syringes) SQ at different injection sites on day 1. <input type="checkbox"/> Maintenance: Beginning day 15, inject 300mg SQ every OTHER week.	2 syringes 2 syringes	Zero _____ Zero
<input type="checkbox"/> Enbrel [®] 50mg <input type="checkbox"/> Enbrel [®] 25mg (etanercept)	<input type="checkbox"/> Initial: Inject 50mg SQ twice weekly for 12 weeks (3 months). <input type="checkbox"/> Maintenance: Inject 50mg SQ once weekly. <input type="checkbox"/> Other _____	<input type="checkbox"/> 24 pens/syringes <input type="checkbox"/> 24 Enbrel Mini cartridges* <input type="checkbox"/> 4 pens/syringes <input type="checkbox"/> 4 Enbrel Mini cartridges* <input type="checkbox"/> Other _____	Zero _____ _____
*AutoTouch device must be provided to the patient by the referring provider. (Contact your Enbrel representative to request the AutoTouch device.)			
<input type="checkbox"/> Humira [®] 40mg [^] (adalimumab)	Initial: <input type="checkbox"/> Psoriasis: Inject 80mg SQ on day 0, 40mg SQ on day 7, then 40mg SQ every OTHER week thereafter. <input type="checkbox"/> Hidradenitis Suppurativa: Inject 160mg SQ on day 0, 80mg SQ on day 14, then 40mg SQ weekly thereafter beginning on day 28. Maintenance: <input type="checkbox"/> Inject 40mg SQ once weekly. <input type="checkbox"/> Inject 40mg SQ every OTHER week. <input type="checkbox"/> Other _____	1 starter package (35-day supply) 1 starter package (28-day supply) 4 pens/syringes 2 pens/syringes <input type="checkbox"/> Other _____	Zero Zero _____ _____
[^] Citrate-free (CF) Humira will be dispensed unless unavailable or otherwise specified.			
<input type="checkbox"/> Ilumya [™] 100mg (tildrakizumab-asmn)	<input type="checkbox"/> Initial: Inject 100mg SQ at week 0 and 4. <input type="checkbox"/> Maintenance: Beginning week 16, inject 100mg SQ every 12 weeks thereafter.	2 syringes 1 syringe	Zero _____ Zero
To order INFLIXIMAB IV infusion products such as Remicade [®] , Inflectra [®] , or Renflexis [®] , please locate the INFLIXIMAB Infusion referral form at https://www.optimedhealthpartners.com/referrals			
<input type="checkbox"/> Other Medication			
Drug _____ <input type="checkbox"/> _____ <input type="checkbox"/>			

Please note: To increase adherence and patient acceptance all medications will be dispensed as pen type injectors unless unavailable or otherwise specified.

Provider Signature _____ **Date** _____

My signature for this prescription confirms that the treatment(s) indicated on this referral is/are medically necessary. I authorize OptiMed and its representatives to act as an agent of mine to initiate and execute the patient's insurance prior authorization process and to provide administrative nursing services and supplies if necessary, in conjunction with the therapy prescribed above.